Optimizing HPV Vaccination for Cervical Cancer Prevention in Women Living with HIV: A Cost-Effectiveness Analysis Across 13 African Countries
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Women living with HIV face a substantially higher risk of persistent HPV infection and cervical cancer, yet HPV vaccination strategies targeting this high-risk population remain limited in many low- and middle-income countries. We evaluated the lifetime health impact and cost-effectiveness of HIV-targeted HPV vaccination strategies across 13 sub-Saharan African countries.
Methods
We developed an age-structured Markov model of HPV infection and cervical cancer in a closed cohort of 100,000 females, stratified by HIV status, and calibrated it separately for each country to age-specific cervical cancer incidence, cervical cancer mortality, and female HIV prevalence. Six HIV-targeted strategies were compared with routine two-dose vaccination at age 14 years. The strategies either provided a booster dose to previously vaccinated WLHIV or combined a booster for previously vaccinated WLHIV with a three-dose primary catch-up course for previously unvaccinated WLHIV. Interventions were delivered at ages 18 or 24 years under standard- and high-coverage assumptions. Outcomes included cervical cancer cases averted, cervical cancer deaths averted among WLHIV, discounted disability-adjusted life-years (DALYs) averted, additional physical vaccine doses, and incremental costs from the health-system and vaccination-programme perspectives.
Results
All HIV-targeted vaccination strategies reduced cervical cancer burden relative to routine vaccination across the 13 countries. Higher-coverage strategies generally produced greater health gains, with mean DALYs averted ranging from 9.05 for booster vaccination at age 24 years to 88.42 for high-coverage combined booster and catch-up vaccination at age 24 years. However, the relative performance of vaccination at ages 18 and 24 varied across strategies and countries. Booster-only strategies achieved the greatest health gains per additional vaccine dose, while combined strategies at higher coverage produced larger overall benefits. From the health-system perspective, 68 of 78 country–strategy comparisons were more effective and less costly than routine vaccination after accounting for avoided cervical cancer treatment costs. From the vaccination-programme perspective, all strategies required additional expenditure.
Conclusions
Targeted HPV vaccination among women living with HIV can reduce cervical cancer burden and may be cost-saving when avoided treatment costs are considered. Higher-coverage combined strategies produced the greatest overall health gains, while booster-only strategies were more dose-efficient, supporting context-specific vaccination decisions.